TITLE

Gatifloxacin: A Review of its Use in the Management of Bacterial Infections

AUTHOR(S)
Perry, C.M.; Ormrod, D.; Hurst, M.; Onrust, S.V.
PUB. DATE
January 2002
SOURCE
Drugs;2002, Vol. 62 Issue 1, p169
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Gatifloxacin is an 8-methoxy fluoroquinolone antibacterial agent. The drug has a broader spectrum of antibacterial activity than the older fluoroquinolones (e.g. ciprofloxacin) and shows good activity against many Gram-positive and Gram-negative pathogens, atypical organisms and some anaerobes. Notably, gatifloxacin is highly active against both penicillin-susceptible and -resistant strains of Streptococcus pneumoniae, a common causative pathogen in community-acquired pneumonia (CAP), acute sinusitis and acute bacterial exacerbations of bronchitis. Gatifloxacin is absorbed well from the gastrointestinal tract (oral bioavailability is almost 100%). Therefore, patients can be switched from intravenous to oral therapy without an adjustment in dosage. High concentrations of gatifloxacin are achieved in plasma and target tissues/fluids. Gatifloxacin has a long plasma elimination half-life, thus allowing once-daily administration. Few clinically significant interactions between gatifloxacin and other drugs have been reported. In patients with CAP, clinical response rates in recipients of intravenous/oral gatifloxacin 400 mg/day ranged from 86.8 to 98.0% and rates of bacterial eradication ranged from 83.1 to 100% (up to 28 days post-treatment). Gatifloxacin showed efficacy similar to that of amoxicillin/clavulanic acid, ceftriaxone (with or without erythromycin) with or without stepdown to clarithromycin, levofloxacin or clarithromycin. Gatifloxacin was as effective as clarithromycin or amoxicillin/clavulanic acid, and was significantly more effective (in terms of clinical response; p < 0.035) than 7 to 10 days' treatment with cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis. In acute sinusitis, gatifloxacin showed clinical efficacy similar to that of clarithromycin, trovafloxacin or amoxicillin/clavulanic acid. Genitourinary infections were also successfully treated with gatifloxacin. Gatifloxacin is generally well tolerated. Its tolerability profile was broadly similar to those of comparator agents in comparative trials. The most common adverse events are gastrointestinal symptoms (oral formulation) and injection site reactions. Conclusions: Gatifloxacin has an extended spectrum of antibacterial activity and provides better coverage of Gram-positive organisms (e.g. S. pneumoniae) than some older fluoroquinolones. The drug has favourable pharmacokinetic properties, is administered once daily and is at least as well tolerated as other fluoroquinolones. Gatifloxacin is a useful addition to the fluoroquinolones currently available for use in the clinical setting and has an important role in the management of adult patients with various bacterial infections. As with other fluoroquinolones, careful control of gatifloxacin usage in the community is important in order to prevent the emergence of bacterial resistance and thus preserve the clinical value of this agent.
ACCESSION #
5885231

 

Related Articles

  • Benefit-Risk Assessment of Linezolid for Serious Gram-Positive Bacterial Infections. Falagas, Matthew E.; Vardakas, Konstantinos Z. // Drug Safety;2008, Vol. 31 Issue 9, p753 

    Linezolid is an oxazolidinone, a new class of antibacterial with a unique mechanism of action, namely inhibition of the formation of a functional 70S initiation complex in the 50S bacterial ribosomal subunit. Linezolid is highly active against multidrug-resistant Gram-positive cocci, including...

  • Antibacterial activity of Flacourtia jangomas and Flacourtia sepiaria. Sarker, Gopal C.; Zahan, Ronok; Alam, M. Badrul; Islam, Md. Saiful; Mosaddik, M. A.; Haque, M. E. Kramul // International Journal of Pharmacy & Life Sciences;2011, Vol. 2 Issue 7, p878 

    The chloroform soluble fraction of Flacourtia jangomas and Flacourtia sepiaria were subjected to in vitro antibacterial screening (by disc diffusion method) against two Gram positive and two Gram negative bacteria to know antimicrobial effectiveness. Chloroform fraction of Flacourtia jangomas...

  • Macrophage Killing of Bacterial and Fungal Pathogens Is Not Inhibited by Intense Intracellular Accumulation of the Lipoglycopeptide Antibiotic Oritavancin. Baquir, Beverlie; Lemaire, Sandrine; Van Bambeke, Francxoise; Tulkens, Paul M.; Lin Lin; Spellberg, Brad // Clinical Infectious Diseases;2012 Supplement 3, Vol. 54, pS229 

    Intact phagocytic effector function is fundamental to host defense against microbial pathogens. Concern has been raised regarding the potential that accumulation of certain agents, including cationic amphiphilic antibiotics, within macrophages could cause a mixed-lipid storage disorder,...

  • Synthesis and Biological Evaluation of 4,6-Diaryl substituted-4,5-dihydro-2-amino Pyrimidines. Venkatesan, J.; Pandeya, S. N.; Selvakumar, D. // Indian Journal of Pharmaceutical Sciences;2007, Vol. 69 Issue 4, p586 

    4,6-Diaryl substituted-4,5-dihydro-2-amino pyrimidines have been synthesized by the reaction of chalcones with guanidine nitrate. Their chemical structures have been confirmed by means of IR and NMR data and by elemental analysis. The compounds were screened for antibacterial activity against 16...

  • In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin. Chris M. Pillar; Mohana K. Aranza; Dineshchandra Shah; Daniel F. Sahm // Journal of Antimicrobial Chemotherapy (JAC);Mar2008, Vol. 61 Issue 3, p595 

    : Objectives To determine the in vitro activity profile of ceftobiprole, a pyrrolidinone cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA), for use as a contemporary baseline to help detect any changes in its activity profile throughout the course of clinical...

  • Staphylococcal Antimicrobial Peptides: Relevant Properties and Potential Biotechnological Applications. Bastos, M. C. F.; Ceotto, H.; Coelho, M. L. V.; Nascimento, J. S. // Current Pharmaceutical Biotechnology;Jan2009, Vol. 10 Issue 1, p38 

    Bacteriocins are bacterial antimicrobial peptides with bactericidal activity against other bacteria. Staphylococcins are bacteriocins produced by staphylococci, which are Gram-positive bacteria with medical and veterinary importance. Most bacteriocins produced by staphylococci are either...

  • ANTIBACTERIAL SUBSTANCES PRODUCED BY MOULDS 2. THE ANTIBACTERIAL SUBSTANCES PRODUCED BY SOME COMMON PENICILLIA. Atkinson, Nancy // Australian Journal of Experimental Biology & Medical Science;Mar1943, Vol. 21 Issue 1, p15 

    The antibacterial substances of a group of active penicillia have been investigated. The moulds could be divided into two groups of which Group 1 owed its activity to the production of penicillin and Group 2 to the production of penicidin.

  • A facile synthesis and studies of some new 4-thiazolidinones and 5-arylidenes. Solankee, A. N.; Patel, K. P.; Patel, R. B. // Advances in Applied Science Research;Feb2012, Vol. 3 Issue 1, p117 

    Condensation of 4-amino-2,3-dimethyl-1-phenyl-3-pyrazoline-5-one with different aromatic and heterocyclic aldehydes in dry toluene give schiff bases 3(a-g), which on reaction with thioglycolic acid and thiolactic acid in dry toluene give the corresponding 2,3-disubstituted-4-thiazolidinones...

  • Daptomycin: Cidecin, Dapcin[sup ®] , LY 146032.  // Drugs in R&D;2002, Vol. 3 Issue 1, p33 

    Adis CommentsDaptomycin [LY 146032, Cidecin™, Dapcin[sup ®]] is an acidic lipopeptide injectable antibacterial derived from Streptomyces roseospors. It has excellent in vitro activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA),...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics